Skip to main content
< Back to news
From left to right: Carmen Eibe, Jordi Martí and Carlos Buesa (Photo: ASEBIO).
 09.12.2015

Director general of Celgene Spain, Jordi Martí, new president of Asebio

The Spanish Bioindustry Association (Asebio)  has renewed its board of directors as part of the celebration of the general assembly, held on December 1. Jordi Martí -Vice President and CEO of Celgene Spain- takes over Regina Revilla -Director of External Relations and Communication of MSD- the head of this institution that was created in 1999 as a meeting platform for those organizations interested in stimulating the national biotechnology scene, of which PCB is a founding member. 

 

In his 2 year´s term as President, Martí will be assisted by Carlos Buesa, director general of Oryzon Genomics (First Vice President); Carmen Eibe, Director of Project Coordination Department of PharmaMar (Second Vice President); and Daniel Ramon, CEO of Biopolis (Third Vice President).

Over the course of the assembly, Asebio also appointed AB Biotics, Grifols, Ingenasa, Esteve, MSD and NeuronBio, as new members of the Boards of Directors. 3P, Amgen, Ferrer, Genetrix, Merck and Vivía Biotech will remain on the company´s Board of Directors.

After his appointment, Jordi Martí revealed “one of the main challenges for this new term will be to work crosswise with all partners, from small SMEs to large companies that make up Asebio, listening to their needs and fighting for their interests.” In reference to the great changes taking place in the sector, the Director of Celgene said that “we need to continue to grow as a strong and cohesive association that places biotechnology as a key tool for scientific development in our country and enhances the participation of the associated companies in international projects to increase competitiveness in R&D&I.”

Related news [+]